News & Press Releases

Of Counsel Michelle Capezza was quoted in a Business Insider article examining the push to expand private credit and other alternative investments into 401(k) retirement plans. The article discusses these developments in light of new regulations proposed by the Department of Labor, as well as ongoing questions about liquidity, valuation, and market volatility within the private credit space.

Michael Arnold, Chair of Mintz’s Employment Practice, was featured on a recent episode of the Corner Office with Elise Powers podcast, where he spoke about leadership, wellbeing, and sustaining a long-term career in Big Law.

Mintz represented Synnovation Therapeutics LLC, a clinical-stage biotechnology company with a diverse pipeline of novel small-molecule targeted therapies in oncology and immunology, in connection with its definitive agreement with Novartis to acquire Synnovation’s wholly-owned subsidiary, Pikavation Therapeutics Inc., and its portfolio of pan mutant selective PI3Kα inhibitor programs, including its lead clinical asset SNV4818.  

Law360 recently highlighted commentary from ITC Practice Co-chair Robert Vlasis in an article examining the rise in Section 337 investigations involving patents and other IP being litigated at the US International Trade Commission for the first time. The piece outlines several developments that may be contributing to this trend, including the Federal Circuit’s Lashify decision and recent USPTO procedural changes affecting PTAB challenges.

Member Jacob Hupart was quoted in a Responsible Investor article about a lawsuit challenging the SEC’s pullback from its long standing “no action” review process for shareholder proposals. In the article, Jacob addresses the legal hurdles facing the plaintiffs as they seek to frame the SEC’s policy shift as actionable under the Administrative Procedure Act.

Mintz advised the underwriters in connection with SAB Biotherapeutics’ $85 million public offering.